Recent Press Releases 02.18.2020 European Commission Approves VYNDAQEL®, the First Treatment in the EU for Transthyretin Amyloid Cardiomyopathy (ATTR-CM) 02.11.2020 XTANDI® (enzalutamide) Demonstrates Significant Improvement in Overall Survival in Phase 3 PROSPER Trial of Patients with nmCRPC 01.31.2020 Pfizer Receives Positive CHMP Opinion for Oncology Biosimilar, RUXIENCE™ (rituximab) 01.28.2020 PFIZER REPORTS FOURTH-QUARTER AND FULL-YEAR 2019 RESULTS 01.23.2020 Pfizer Vaccines Launches Global Centers of Excellence Network to Conduct Real-World Research on Vaccine-Preventable Diseases Affecting Adults 01.23.2020 Pfizer’s Greenstone and Digital Men’s Health Clinic Roman Collaborate to Offer Patients Remote Access to the Only FDA-Approved Authorized Generic Version of Viagra® (sildenafil citrate) 01.07.2020 Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference 01.06.2020 BAVENCIO Significantly Improved Overall Survival in Patients With Locally Advanced or Metastatic Urothelial Carcinoma 12.23.2019 Theravance Biopharma and Pfizer Inc. Enter Global License Agreement for Skin-Targeted, Locally-Acting Pan-Janus Kinase (JAK) Inhibitor Program 12.18.2019 U.S. FDA Accepts and Grants Priority Review to sNDA for BRAFTOVI® (encorafenib) in Combination with ERBITUX® (cetuximab) (BRAFTOVI Doublet) for the Treatment of BRAFV600E-Mutant Metastatic Colorectal Cancer After Prior Therapy 1 of 158 next › Media Contacts Get to Know Us Company Fact Sheet Featured Stories Press Kits @Pfizer @Pfizer_News by pfizer Tweets by pfizer_news
